Clinical Trials Directory

Trials / Completed

CompletedNCT02903511

Feasibility Study of Metformin Therapy in ADPKD

Feasibility Study of Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
56 (actual)
Sponsor
University of Colorado, Denver · Academic / Other
Sex
All
Age
30 Years – 60 Years
Healthy volunteers
Not accepted

Summary

This study is being done to determine if treatment with metformin, a drug widely used for the treatment of diabetes type 2, is safe and well tolerated by individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who are not diabetic and who have slightly decreased kidney function. The study will also evaluate the effects of metformin on kidney growth and kidney function.

Detailed description

Patients with ADPKD are still in need for a well-tolerated treatment that can be used long-term to prevent cyst growth and kidney function decline. Metformin has a long track record of a low risk-to-benefit profile in patients with diabetes or at risk for diabetes. Metformin inhibits two key processes responsible for the growth of polycystic kidneys, i.e. fluid secretion and cell proliferation, as shown in cell cultures and animal models of ADPKD. Experiments in animal models of chronic kidney disease demonstrate that metformin administration prevents kidney fibrosis and preserves kidney function. Diabetic patients who are treated with metformin appear to develop less kidney failure and live longer than patients who are treated with other anti-diabetic medications. Therefore this drug is promising for people with ADPKD, with the potential to slow cyst enlargement and preserve kidney function.

Conditions

Interventions

TypeNameDescription
DRUGMetforminMonitoring of safety and tolerability
DRUGPlaceboMonitoring of safety and tolerability

Timeline

Start date
2016-11-01
Primary completion
2020-08-17
Completion
2020-08-17
First posted
2016-09-16
Last updated
2021-09-05
Results posted
2021-09-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02903511. Inclusion in this directory is not an endorsement.